



Wednesday 3rd March 2021
15.00 – 16.00 CET

“To be OR not to be (degraded)”
Assays and HTS of the cellular protein degradation machinery

Speakers

Stefan Lohmer, PhD - CEO and CSO
Fernanda Ricci, PhD - High Content Analysis Unit Manager

Register at:

https://axxam.zoom.us/webinar/register/WN_vKSg2TReScOd91ahqyT2Ag

**** Please note: this is a free webinar and places are limited. After registering, you will receive a confirmation e-mail containing your personal link to access the webinar. Early registration is strongly recommended as participation will be confirmed on a first-come first-served basis. ****

Millions of protein molecules are synthesized per minute in each cell, and simultaneously, millions of protein molecules are degraded, which is under tight control.

This webinar will provide you with insights on different approaches available to develop smart and functional assays for the identification of molecules able to modulate the protein degradation pathways.

The first part of the webinar is dedicated to the lysosome mediated protein degradation pathway, whereas the second part to the proteasome mediated degradation pathway.

Keywords: Autophagy, lysosome, proteasome, protein aggregation, tandem fluorescent timers, PROTAC, E3-Ligases, functional assays for HCS and HTS

About the Speakers

Stefan Lohmer

Stefan is Axxam's co-founder, Chairman of the Board of Directors and Chief Executive Officer. Prior to founding Axxam, he was head of the assay development unit at the Bayer Research Centre in Milan and the Head of Genomics worldwide for Bayer AG. He was responsible for generating and managing Bayer's external genomic alliances with Millennium and Lion Bioscience. Stefan Lohmer joined Bayer in 1992. He holds a degree in Molecular Biology and Biochemistry from the University of Cologne and completed his PhD at the Max Planck Institute for Plant Breeding in Cologne.



Fernanda Ricci

Fernanda is manager of the High Content Analysis Unit at Axxam with ten years of experience in the field of Screening Technologies for drug discovery and with focused expertise in imaging and phenotypic cell-based assays. She holds a PhD in Molecular Biophysics and a PostDoc where she succeeded in developing several phenotypic assays based both on gene editing (siRNA technologies) and/or small molecule screening approaches. Moreover, Fernanda has 12 peer-reviewed publications, two international and one national patents, an image analysis pipeline published on the CellProfiler website and she was the winner of the Grand Prize of 2016 JALA & JBS Art of Science Contest.

